EUCTR2010-022422-32-GB进行中（未招募）不适用
A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib - REMoDL-B v1.0
niversity Hospital Southampton NHS Foundation Trust0 个研究点目标入组 940 人开始时间: 2010年11月8日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 940
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically confirmed DLBCL, expressing CD20. Sufficient diagnostic material should be available to forward to HDMS for gene expression profiling and central pathology review. • Not previously treated for lymphoma and fit enough to receive combination chemoimmunotherapy with curative intent. • Age >18 years • Stage IAX (bulk defined as lymph node diameter >10cm) to stage IV disease and deemed to require a full course of chemotherapy • ECOG performance status 0-2 • Adequate bone marrow function with platelets >100x109/L; neutrophils >1.0x109/L at study entry, unless lower figures are attributable to lymphoma. • Serum creatinine <150µmol/L, serum bilirubin <35µmol/L and transaminases <2.5x upper limit of normal at the time of study entry, unless attributable to lymphoma. • Cardiac function sufficient to tolerate 300mg/m2 of doxorubicin. A pre-treatment echocardiogram is not mandated, but recommended in patients considered at higher risk of anthracycline cardiotoxicity. • No concurrent uncontrolled medical condition. • Life expectancy >3 months • Adequate contraceptive precautions for all patients of child bearing potential • A negative serum pregnancy test for females of child bearing potential or those <2 years after the onset of the menopause • Patients will have provided written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Previous history of treated or untreated indolent lymphoma. However newly diagnosed patients with DLBCL who are found to also have small cell infiltration of the bone marrow or other diagnostic material (discordant lymphoma) will be eligible. • Uncontrolled systemic infection • History of cardiac failure of uncontrolled angina • Clinical CNS involvement • Serological positivity for Hepatitis C, B or known HIV infection • Serious medical or psychiatric illness likely to affect participation or that may compromise the ability to give informed consent. • Active malignancy other than fully excised squamous or basal cell carcinoma of the skin or carcinoma in situ of the uterine cervix in the preceding 5 years. • History of allergic reaction to substances containing boron or mannitol • Patient unwilling to abstain from green tea and preparations made from green tea as bortezomib may interact with these. • Any co-existing medical or psychological condition that would compromise ability to give informed consent.
研究者
相似试验
进行中（未招募）
3 期
An evaluation of therapy for B-cell lymphoma with BortezomibCancerISRCTN51837425Southampton University Hospitals NHS Trust (UK)1,128
已完成
2 期
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCancer of Unknown Primary SiteNCT03498521Hoffmann-La Roche529
已完成
3 期
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With BortezomibLymphoma, Large B-Cell, DiffuseNCT01324596University Hospital Southampton NHS Foundation Trust1,132
尚未招募
1 期
Effect of Ayurvedic medicine- Nisakathakadi kashayam in Diabetes mellitusCTRI/2017/10/010078Government Ayurveda College
招募中
2 期
Pediatric Precision Laboratory Advanced Neuroblastoma TherapyNeuroblastomaNCT02559778Giselle Sholler500